• TRM$ 3.461,92 +1,37 % +$ 46,82TRM oficial (Superintendencia Financiera), vigente del 21 nov al 23 nov
  • Euro$ 3.804,64 +1,37 % +$ 51,45Referencia: TRM cruzada con la tasa del Banco Central Europeo del 20 nov; no es la cotización de mercado
  • Peso mexicano$ 181,56 +1,37 % +$ 2,45Referencia: TRM cruzada con la tasa del Banco Central Europeo del 20 nov; no es la cotización de mercado
← Volver a la comunidad
General

Why are FTC serial-acquisition lawsuits and state mini-HSR laws breaking the private equity healthcare roll-up model?

Federal antitrust lawsuits targeting serial acquisitions alongside state mini-HSR pre-closing review laws are dismantling the private equity healthcare and veterinary roll-up model by blocking buyout sponsors from stealthily consolidating local medical clinics below federal Hart-Scott-Rodino reporting thresholds to extract regional monopoly pricing.

For over a decade, the classic private equity buy-and-build arbitrage relied on acquiring a platform practice in anesthesiology, dermatology, dental care, or veterinary medicine and executing dozens of bolt-on acquisitions valued under the $119.5 million HSR filing threshold. Once a sponsor captured dominant local market share, it used Management Services Organizations (MSOs) to hike out-of-network billing rates, execute real estate sale-leasebacks, and load the clinical entity with floating-rate debt to fund dividend recapitalizations. However, following the FTC's landmark enforcement actions against U.S. Anesthesia Partners and JAB Consumer Partners' veterinary clinic empire under Section 7 of the Clayton Act, serial roll-ups are now treated as unlawful creeping monopolies.

Even more damaging to buyout Internal Rates of Return (IRRs) is the wave of state-level ”mini-HSR” statutes and Corporate Practice of Medicine (CPOM) crackdowns enacted across California, Oregon, Illinois, New York, and Massachusetts. By empowering state Attorneys General to review, delay, or block sub-threshold healthcare M&A and outlawing MSO control agreements that interfere with clinical staffing, regulators have frozen the traditional multiple-expansion exit pathway. Will this federal and state antitrust offensive protect patients from debt-fueled medical price gouging, or will it starve independent physician and veterinary practices of vital growth capital?

What will be the primary impact of cracking down on PE healthcare roll-ups?

0 votos

Comentarios

Sé respetuoso. Los comentarios que reporten varias personas se ocultan hasta que los revise un moderador.

Para leer no necesitas cuenta; solo para comentar. Entras con un código que te llega al correo o con tu cuenta de Google. Mostramos solo el nombre que elijas; nunca tu correo.